bioMérieux
France · FR0013280286 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +2.3% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 9.7% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 74% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €3.6B | €3.7B | €4.0B | €4.1B |
| Operating profit | €587M | €439M | €589M | €521M |
| Net profit to shareholders | €452M | €358M | €432M | €398M |
| Cash from operations | €475M | €445M | €667M | €788M |
| Cash | €553M | €352M | €450M | €570M |
| Total assets | €5.2B | €5.3B | €5.8B | €5.6B |
| Equity | €3.6B | €3.8B | €4.2B | €4.1B |
What they do
In the company's own words, from the annual report.
bioMérieux est un des leaders mondiaux du domaine du diagnostic in vitro destiné à des applications cliniques et industrielles. Le Groupe conçoit, développe, produit et commercialise des systèmes de diagnostic (réactifs, instruments et logiciels). Il est présent dans plus de 160 pays à travers une implantation dans 46 pays et un large réseau de distributeurs
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.